MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs Veraxa Biotech (VRXA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BridgeBio Oncology Therapeutics (BBOT) has outperformed Veraxa Biotech (VRXA) over the past year, losing 85.4% versus a loss of 90.1%. Veraxa Biotech is the larger company by market cap ($147.1 million vs $145.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-85.39%VRXA-90.10%
+147%+22%-102%
Nov 21, 20251 yearNov 20, 2026
BBOT-82.64%VRXA-89.58%
+110%+5%-100%
Sep 30, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus VRXA key metrics
MetricBBOTVRXA
Share price$1.81$1.04
Market cap$145.25M$147.06M
1-day change-2.69%+0.97%
YTD return-85.54%-90.25%
1-year return-85.39%-90.10%
P/E ratio (TTM)3.42—
EPS (TTM)$0.53$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-134.04M—
52-week high$14.87$27.36
52-week low$1.79$0.90
Distance from 52-week high-87.83%-96.20%
Analyst consensusstrong_buy—
Avg. price target upside+1060.22%—
Average volume631.56K267.82K
Shares outstanding80.25M141.41M
Employees92—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Veraxa Biotech

VRXA stock →

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.

Health Care · Biotechnology: Pharmaceutical Preparations

BBOT vs VRXA FAQ

Which is bigger, BridgeBio Oncology Therapeutics or Veraxa Biotech?

Veraxa Biotech (VRXA) is larger, with a market capitalization of $147.06M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).

Which stock has performed better over the past year, BBOT or VRXA?

BBOT returned -85.39% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Oncology Therapeutics and Veraxa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons